Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial - Seite 2

Toledo Roundtable 27 October 2020
Galapagos cordially invites institutional investors and analysts to attend our inaugural Roundtable dedicated to Toledo. The one-hour Roundtable will be webcast on 27 October 2020, starting at 16.00 CET/9 am ET. Please RSVP to [e-mail].

About Toledo

“Toledo” is a code name for a novel target class discovered by Galapagos for autoimmune and fibrotic diseases. This Toledo platform delivers small molecule inhibitors of Toledo targets with different selectivity profiles. GLPG3970 has immunomodulatory activity with a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. GLPG3970 has shown encouraging preclinical activity in a number of inflammatory diseases, including inflammatory bowel diseases, rheumatoid arthritis, and psoriasis. Galapagos is executing on a broad program to discover and develop multiple series of compounds with different selectivity on Toledo targets, aimed at treating a broad range of autoimmune conditions with still important unmet medical need.

GLPG3970 is an investigational drug and its efficacy and safety have not been established.

For information about clinical trials with GLPG3970: www.clinicaltrials.gov.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
[phone]

Sofie Van Gijsel
Senior Director Investor Relations
[phone]
[e-mail]

Media:
Carmen Vroonen
Global Head of Communications & Public Affairs
[phone]

Anna Gibbins
Senior Director Therapeutic Areas Communications
[phone]
[e-mail]

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG3970 may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG3970 due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties and that Galapagos’ estimations regarding its GLPG3970 development program and regarding the commercial potential of GLPG3970, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.